- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01350960
Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH
A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC5001 Administered to Healthy Subjects and Subjects With Familial Hypercholesterolemia (FH)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Leiden, Nederland, 2333
- Centre for Huma Drug Research (CHDR)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Healthy male or female subjects and subjects with heterozygous Familial Hypercholesterolemia
- Healthy male or female subjects, age 18 to 65 years, inclusive will be enrolled in Cohorts 1 through 4.
- In Cohort 5, male or female subjects with heterozygous Familial Hypercholesterolemia, confirmed through genetic testing, without a history of cardiovascular disease (e.g. coronary artery, peripheral artery or cerebrovascular disease), hypertension or diabetes mellitus age 18-45 years, inclusive, will be enrolled.
- BMI of 18-33 kg/m2
Screening hematology, clinical chemistries, coagulation and urinalysis consistent with overall good health and the following criteria are met:
- LDL ≥.3.24 mmol/L (≥ 100 mg/dL)
- Triglycerides (fasted) < 4.5 mmol/L (< 398 mg/dL)
- ALT within normal limits for healthy subjects and ALT < 2 x ULN for FH subjects
Exclusion Criteria:
Any uncontrolled or active major systemic disease including, but not limited to: cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric, or neoplastic disorder with metastatic potential
- History or presence of malignancy within the past year is an exclusion criterion. Subjects who have been successfully treated with no recurrence of basal cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled.
- Active acute or chronic infection, including, but not limited to: upper airway infection, urinary tract infection, and skin infection
- Use of prescription medication within 14 days prior to the planned first drug administration and throughout the study. For the FH subjects statin therapy (and other lipid lowering therapies) will be prohibited within 4 weeks prior to the first study drug administration.
- Use of non-prescription or over-the-counter medications is prohibited within 7 days prior to the planned first drug administration and throughout the study. This includes all vitamins, herbal supplements, or remedies. An exception can be made for medication or supplements that in the opinion of both the investigator and the Sponsor do not complicate or compromise the study or interfere with the study objectives.
- Positive results on the following Screening laboratory tests: urine or serum pregnancy test (women only), alcohol breath test, urine drugs of abuse, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: saline 0.9%
|
3 weekly SC injections
|
Eksperimentell: Cohort 1
0.5 mg/kg in Healthy Subjects
|
3 weekly SC injections
|
Eksperimentell: Cohort 2
1.5 mg/kg in Healthy subjects
|
3 weekly SC injections
|
Eksperimentell: Cohort 3
5.0 mg/kg in Healthy subjects
|
3 weekly SC injections
|
Eksperimentell: Cohort 4
10 mg/kg in Healthy subjects
|
3 weekly SC injections
|
Eksperimentell: Cohort 5
TBD mg/kg in FH subjects
|
3 weekly SC injections
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Safety and Tolerability
Tidsramme: Regularly over 78 days
|
Safety evaluation will assess adverse event (AE) profile, clinical laboratory safety tests, vital signs and ECG monitoring
|
Regularly over 78 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Peak Plasma Concentration (Cmax) of SPC5001
Tidsramme: up to 78 days
|
up to 78 days
|
Lipid lowering effect
Tidsramme: Through out the study
|
Through out the study
|
Area under the plasma concentration versus time curve (AUC) of SPC5001
Tidsramme: up to 78 days
|
up to 78 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Koos Burggraaf, MD PhD, Centre for Human Drug Research (CHDR)
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SPC5001-901
- EudraCT 2011-000489-36
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Saline 0.9%
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiFullførtOral mukositt | Hode- og nakkekreftTyrkia
-
TC Erciyes UniversityFullført